New Zealand Adds Two Prostate Drugs To Coverage List
This article was originally published in PharmAsia News
New Zealand's drug-management agency, Pharmac, has decided to cover drugs for treating a pair of prostate problems. Merck's Fintral (finasteride) and AstraZeneca's Bicalox (bicalutamide) are to be covered beginning Nov. 1 for advanced prostate cancer. Pharmac's medical director said the decision to include the drugs in its formicary was based on the fact some patients do not respond to other available drugs. He estimated 3,000 men could be treated with Fintral by 2011, 300 with Bicalox. (Click here for more
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.